<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults - Derry, S - 2017 | Cochrane Library</title> <meta content="Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults - Derry, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012638.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults - Derry, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012638.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012638.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults" name="citation_title"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="andrew.moore@omkltd.org" name="citation_author_email"/> <meta content="Ewan D McNicol" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="Daniel B Carr" name="citation_author"/> <meta content="Tufts University School of Medicine" name="citation_author_institution"/> <meta content="Mairead McIntyre" name="citation_author"/> <meta content="West Hoe Surgery" name="citation_author_institution"/> <meta content="Bee Wee" name="citation_author"/> <meta content="Churchill Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012638.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012638.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012638.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012638.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Analgesics, Opioid [administration &amp; dosage]; Anti‐Inflammatory Agents, Non‐Steroidal [*administration &amp; dosage, adverse effects]; Cancer Pain [*drug therapy]; Randomized Controlled Trials as Topic; Withholding Treatment [statistics &amp; numerical data]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012638.pub2&amp;doi=10.1002/14651858.CD012638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012638\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012638\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","pl","fr","zh_HANS","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012638.pub2",title:"Oral nonsteroidal anti\\u2010inflammatory drugs (NSAIDs) for cancer pain in adults",firstPublishedDate:"Jul 12, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012638.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012638.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012638.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012638.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012638.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012638.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012638.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012638.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012638.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012638.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4609 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012638.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/appendices#CD012638-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0002">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0003">Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>R Andrew Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0005">Ewan D McNicol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0006">Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0007">Daniel B Carr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0008">Mairead McIntyre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information#CD012638-cr-0009">Bee Wee</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information/en#CD012638-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012638.pub2">https://doi.org/10.1002/14651858.CD012638.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012638-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012638-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012638-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012638-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012638-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012638-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012638-abs-0001" lang="en"> <section id="CD012638-sec-0001"> <h3 class="title" id="CD012638-sec-0001">Background</h3> <p>Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Non‐opioid drugs are commonly used to treat cancer pain, and are recommended for this purpose in the World Health Organization (WHO) cancer pain treatment ladder, either alone or in combination with opioids. </p> <p>A previous Cochrane review that examined the evidence for nonsteroidal anti‐inflammatory drugs (NSAIDs) or paracetamol, alone or combined with opioids, for cancer pain was withdrawn in 2015 because it was out of date; the date of the last search was 2005. This review, and another on paracetamol, updates the evidence. </p> </section> <section id="CD012638-sec-0002"> <h3 class="title" id="CD012638-sec-0002">Objectives</h3> <p>To assess the efficacy of oral NSAIDs for cancer pain in adults, and the adverse events reported during their use in clinical trials. </p> </section> <section id="CD012638-sec-0003"> <h3 class="title" id="CD012638-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to April 2017, together with reference lists of retrieved papers and reviews, and two online study registries. </p> </section> <section id="CD012638-sec-0004"> <h3 class="title" id="CD012638-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, single‐blind, or open‐label studies of five days' duration or longer, comparing any oral NSAID alone with placebo or another NSAID, or a combination of NSAID plus opioid with the same dose of the opioid alone, for cancer pain of any pain intensity. The minimum study size was 25 participants per treatment arm at the initial randomisation. </p> </section> <section id="CD012638-sec-0005"> <h3 class="title" id="CD012638-sec-0005">Data collection and analysis</h3> <p>Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality and potential bias. We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD012638-sec-0006"> <h3 class="title" id="CD012638-sec-0006">Main results</h3> <p>Eleven studies satisfied inclusion criteria, lasting one week or longer; 949 participants with mostly moderate or severe pain were randomised initially, but fewer completed treatment or had results of treatment. Eight studies were double‐blind, two single‐blind, and one open‐label. None had a placebo only control; eight compared different NSAIDs, three an NSAID with opioid or opioid combination, and one both. None compared an NSAID plus opioid with the same dose of opioid alone. Most studies were at high risk of bias for blinding, incomplete outcome data, or small size; none was unequivocally at low risk of bias. </p> <p>It was not possible to compare NSAIDs as a group with another treatment, or one NSAID with another NSAID. Results for all NSAIDs are reported as a randomised cohort. We judged results for all outcomes as very low‐quality evidence. </p> <p>None of the studies reported our primary outcomes of participants with pain reduction of at least 50%, and at least 30%, from baseline; participants with Patient Global Impression of Change (PGIC) of much improved or very much improved (or equivalent wording). With NSAID, initially moderate or severe pain was reduced to no worse than mild pain after one or two weeks in four studies (415 participants in total), with a range of estimates between 26% and 51% in individual studies. </p> <p>Adverse event and withdrawal reporting was inconsistent. Two serious adverse events were reported with NSAIDs, and 22 deaths, but these were not clearly related to any pain treatment. Common adverse events were thirst/dry mouth (15%), loss of appetite (14%), somnolence (11%), and dyspepsia (11%). Withdrawals were common, mostly because of lack of efficacy (24%) or adverse events (5%). </p> </section> <section id="CD012638-sec-0007"> <h3 class="title" id="CD012638-sec-0007">Authors' conclusions</h3> <p>There is no high‐quality evidence to support or refute the use of NSAIDs alone or in combination with opioids for the three steps of the three‐step WHO cancer pain ladder. There is very low‐quality evidence that some people with moderate or severe cancer pain can obtain substantial levels of benefit within one or two weeks. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012638-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012638-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012638-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012638-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012638-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012638-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012638-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012638-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012638-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012638-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012638-abs-0004" lang="en"> <h3>Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults</h3> <p><b>Bottom line</b> </p> <p>There is no high‐quality evidence to prove that NSAIDs are useful in treating people with cancer pain. Nor is there evidence to disprove that they are useful. Very low‐quality evidence shows that some people with moderate or severe cancer pain have pain much reduced within one or two weeks. </p> <p><b>Background</b> </p> <p>One person in two or three who gets cancer will suffer from pain that becomes moderate or severe in intensity. The pain tends to get worse as the cancer progresses. In 1986, the World Health Organization (WHO) recommended taking morphine‐like drugs (opioids) for moderate to severe pain from cancer, and non‐opioid drugs like NSAIDs, alone for mild to moderate pain, or alongside opioids in people with moderate to severe pain. There are many different types of NSAIDs. Common NSAIDs are ibuprofen and diclofenac. </p> <p><b>Study characteristics</b> </p> <p>In this review we set out to examine the evidence on how well NSAIDs worked (alone or with morphine‐like drugs) in adults with cancer pain. We also wanted to know how many people had side effects, and how severe they were. </p> <p>In April 2017, we found 11 studies with 949 participants. They compared NSAID with NSAID, or NSAID with opioid drug (morphine or codeine). No studies looked at using NSAID together with an opioid‐like morphine, which is how they are often used. The studies were small and of poor quality. They used different designs and different ways of showing their pain results. Outcomes important to people with cancer pain were often not reported. Many different NSAIDs were tested, and it was not possible to make sensible comparisons. </p> <p><b>Key findings</b> </p> <p>With an NSAID, initially moderate or severe cancer pain was reduced to no worse than mild pain after one or two weeks in 1 in 4 (26%) to 1 in 2 (51%) people in four studies. </p> <p>Side‐effect reporting was poor. Two serious side effects were reported with NSAIDs, and 22 deaths, but these were not related to pain treatment. Common side effects were thirst/dry mouth (1 in 7; 15%), loss of appetite (1 in 7; 14%), sleepiness (1 in 10; 11%), and heartburn (1 in 10; 11%). One in four people stopped taking NSAIDs because the drug did not work, and 1 in 20 stopped because of side effects. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was very low. Very low‐quality evidence means that we are very uncertain about the impact of an NSAID alone for treating cancer pain. We do not know whether using NSAIDs together with an opioid such as codeine or morphine is worthwhile. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012638-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012638-sec-0095"></div> <h3 class="title" id="CD012638-sec-0096">Implications for practice</h3> <section id="CD012638-sec-0096"> <section id="CD012638-sec-0097"> <h5 class="title">For people with cancer pain</h5> <p>The amount and quality of evidence around the use of NSAIDs for treating cancer pain is very low. The amount of evidence we have indicates that oral NSAIDs may have pain‐relieving effects in some people with cancer pain, but we are very unsure of this. No judgement can be made about adverse events or withdrawals. </p> </section> <section id="CD012638-sec-0098"> <h5 class="title">For clinicians</h5> <p>The amount and quality of evidence around the use of NSAIDs for treating cancer pain is very low. There is very limited evidence supporting the use of NSAIDs as part of the WHO ladder, and none on any additional pain‐relieving effects when combined with strong opioids. The small amount of evidence we have indicates that NSAIDs may have pain‐relieving effects in some people with cancer pain, but we are very unsure of this. No judgement can be made about adverse events or withdrawals. We have no evidence about which drug at which dose may be more or less effective. </p> </section> <section id="CD012638-sec-0099"> <h5 class="title">For policy makers</h5> <p>The amount and quality of evidence around the use of NSAIDs for treating cancer pain is very low. There is very limited evidence supporting the use of NSAIDs as part of the WHO ladder, and none on any additional pain‐relieving effects when combined with oral strong opioids. The small amount of evidence we have indicates that NSAIDs may have pain‐relieving effects in some people with cancer pain, but we are very unsure of this. No judgement can be made about adverse events or withdrawals. We have no evidence about which drug at which dose may be more or less effective. </p> </section> <section id="CD012638-sec-0100"> <h5 class="title">For funders</h5> <p>The amount and quality of evidence around the use of NSAIDs for treating cancer pain is very low. There is very limited evidence supporting or refuting the use of NSAIDs as part of the WHO ladder, and none on any additional pain‐relieving effects when combined with oral strong opioids. The small amount of evidence we have indicates that NSAIDs may have pain‐relieving effects in some people with cancer pain, but we are very unsure of this. No judgement can be made about adverse events or withdrawals. We have no evidence about which drug at which dose may be more or less effective. </p> </section> </section> <h3 class="title" id="CD012638-sec-0101">Implications for research</h3> <section id="CD012638-sec-0101"> <section id="CD012638-sec-0102"> <h5 class="title">General</h5> <p>This review on NSAIDs for cancer pain reveals major problems with the evidence available. The WHO pain ladder is now over 30 years old, and remains probably the most‐used and best‐understood pain guidance worldwide. Despite its obvious importance there are few exemplars for how best to perform cancer pain studies with non‐opoid drugs like NSAIDs, alone or in combination with opioids. We know of no ongoing studies. </p> </section> <section id="CD012638-sec-0103"> <h5 class="title">Design</h5> <p>Several methodological issues stand out.</p> <p>The first is the use of outcomes of value to people with cancer pain. Existing trials are designed more for purposes of registration and marketing than informing and improving clinical practice, often because the outcomes chosen are average pain scores, or statistical differences, rather than how many individuals achieve satisfactory pain relief. In the situation where initial pain is mild or moderate initially, some consideration needs to be given to what constitutes a satisfactory outcome. The situation is somewhat different to that of strong opioids in cancer pain that are used for moderate to severe pain. </p> <p>The second is the time taken to achieve good pain relief. We have no information about what constitutes a reasonable time to achieve a satisfactory result. Initially this may best be approached with a Delphi methodology. </p> <p>The third is design. Studies with cross‐over design often have significant attrition. Parallel group designs may be preferable, and while this is a matter of debate (<a href="./references#CD012638-bbs2-0050" title="BellRF , WisløffT , EcclestonC , KalsoE . Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. British Journal of Cancer2006;94(11):1559‐67. [DOI: 10.1038/sj.bjc.6603162] ">Bell 2006</a>), considerable thinking has already gone into study design. </p> <p>The fourth is size. The studies were small, and, combined with cross‐over design and consequent attrition, ended up reporting on very few participants. Much larger studies of several hundred participants or more are needed. </p> <p>The fifth is the dose of opioid allowable in add‐on studies to test the analgesic efficacy or effectiveness of oral NSAIDs. In the circumstance of high oral opioid doses, additional benefit is unlikely to be measurable, and some upper limit of opioid dose may be needed. </p> <p>The sixth is that in the current era of precision medicine investigator may have an opportunity to conduct clinical trials involving specific aetiologies of cancer pain, or accrue sufficient numbers of participants to conduct well‐powered subgroup analyses. </p> <p>There are some other design issues that might be addressed. Most important might be a clear decision concerning the gold‐standard treatment comparator. Placebo‐controlled studies in cancer pain are unlikely to be ethically feasible unless rescue morphine is freely available (<a href="./references#CD012638-bbs2-0050" title="BellRF , WisløffT , EcclestonC , KalsoE . Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. British Journal of Cancer2006;94(11):1559‐67. [DOI: 10.1038/sj.bjc.6603162] ">Bell 2006</a>). It may be that low‐dose oral morphine is a suitable comparator, as a suggested alternative treatment for mild to moderate pain (<a href="./references#CD012638-bbs2-0121" title="TwycrossR , WilcockA , HowardP . Palliative Care Formulary. PCF5. Nottingham: Palliativedrugs.com Ltd, 2014. [ISBN: 978‐0‐9552547‐9‐6] ">Twycross 2014</a>). </p> </section> <section id="CD012638-sec-0104"> <h5 class="title">Measurement (endpoints)</h5> <p>Trials need to consider the additional endpoints of no worse than mild pain and the impact of morphine on symptoms that raise serious concerns such as consciousness, appetite, and thirst. The choice of measures to be used in cancer pain studies is not necessarily straightforward. </p> </section> <section id="CD012638-sec-0105"> <h5 class="title">Other</h5> <p>Prospective randomised trials are the obvious design of choice, but other pragmatic designs may be worth considering. Studies could incorporate initial randomisation but a pragmatic design in order to provide immediately‐relevant information on effectiveness and costs. Such designs in pain conditions have been published (<a href="./references#CD012638-bbs2-0098" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , WiffenP , et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] ">Moore 2010b</a>). </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012638-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012638-sec-0029"></div> <div class="table" id="CD012638-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>NSAID for cancer pain ‐ non‐controlled data</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer pain </p> <p><b>Settings:</b> inpatient or outpatient </p> <p><b>Intervention:</b> any NSAID, and dose </p> <p><b>Comparison:</b> no control ‐ cohort of treated participants </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with NSAID</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants with at least 30% or at least 50% reduction in pain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC much or very much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain no worse than mild at one or two weeks (or equivalent)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Range of estimates from 260 in 1000 to 510 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 studies</p> <p>415 participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 serious adverse events reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 studies</p> <p>949 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Dry mouth 10%</p> <p>Loss of appetite 4%</p> <p>Somnolence 9%</p> <p>Dyspepsia 9%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Variously reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>All cause 23%</p> <p>Lack of efficacy 24%</p> <p>Adverse event 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Variously reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 deaths, not clearly related to treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 studies</p> <p>949 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD012638-bbs2-0073" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 7 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> This research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012638-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012638-sec-0030"></div> <p>A previous Cochrane review that examined the evidence for nonsteroidal anti‐inflammatory drugs (NSAIDs) or paracetamol, alone or combined with opioids, for cancer pain was withdrawn in 2015 because it was out of date (<a href="./references#CD012638-bbs2-0133" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>); the date of the last search was 2005. </p> <p>This is one of three reviews on the efficacy and safety of oral non‐opioid medicines to treat cancer pain, in this case focusing on oral NSAIDs in adults. A separate review will examine the efficacy of NSAIDs for cancer pain in children (<a href="./references#CD012638-bbs2-0059" title="CooperTE , HeathcoteLC , AndersonB , GrégoireMC , LjungmanG , EcclestonC . Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD012563] ">Cooper 2017</a>). The other review will examine oral paracetamol (acetaminophen) for cancer pain in both adults and children (<a href="./references#CD012638-bbs2-0129" title="WiffenPJ , DerryS , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD012637] ">Wiffen 2017a</a>). </p> <section id="CD012638-sec-0031"> <h3 class="title" id="CD012638-sec-0031">Description of the condition</h3> <p>Cancer is estimated to cause over eight million deaths per annum ‐ approximately 13% of deaths worldwide (<a href="./references#CD012638-bbs2-0085" title="International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 7 February 2017). ">IARC 2012</a>). Globally, 32 million people are living with cancer, and detailed information for individual countries is available on the WHO website for the International Agency for Research on Cancer (<a href="http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx" target="_blank">http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx</a>). In the UK alone in 2014, there were around 350,000 new cases of cancer annually, with around 50% of people surviving for 10 years or more after diagnosis (<a href="./references#CD012638-bbs2-0055" title="Cancer Statistics for the UK. www.cancerresearchuk.org/health‐professional/cancer‐statistics (accessed 7 February 2017). ">Cancer Research UK 2016</a>). </p> <p>Cancer pain is perhaps one of the most feared symptoms associated with the disease. Pain may be the first symptom to cause someone to seek medical advice that leads to a diagnosis of cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain (<a href="./references#CD012638-bbs2-0110" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353(9165):1695‐700. [DOI: 10.1016/S0140‐6736(99)01310‐0] ">Portenoy 1999</a>). Pain can occur at any time as the disease progresses, but the frequency and intensity of pain tends to increase as the cancer advances (<a href="./references#CD012638-bbs2-0110" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353(9165):1695‐700. [DOI: 10.1016/S0140‐6736(99)01310‐0] ">Portenoy 1999</a>; <a href="./references#CD012638-bbs2-0122" title="Van denBeuken‐van EverdingenMHJ , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51:1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">Van den Beuken‐van Everdingen 2016</a>). For people with advanced cancer, some 75% to 90% will experience pain having a major impact on daily living (<a href="./references#CD012638-bbs2-0128" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). Pain had a significant negative correlation with quality of life in people with cancer in China, Japan, and Palestine, for example (<a href="./references#CD012638-bbs2-0064" title="DengD , FuL , ZhaoYX , WuX , ZhangG , LiangC , et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. American Journal of Hospital Palliative Care2012;29(1):53‐9. [DOI: 10.1177/1049909111418636] ">Deng 2012</a>; <a href="./references#CD012638-bbs2-0067" title="DreidiMM , Hamdan‐MansourAM . Pain, sleep disturbance, and quality of life among Palestinian patients diagnosed with cancer. Journal of Cancer Education2016;31(4):796‐803. [DOI: 10.1007/s13187‐015‐0946‐5] ">Dreidi 2016</a>; <a href="./references#CD012638-bbs2-0094" title="MikanF , WadaM , YamadaM , TakahashiA , OnishiH , IshidaM , et al. The association between pain and quality of life for patients with cancer in an outpatient clinic, an inpatient oncology ward, and inpatient palliative care units. American Journal of Hospital Palliative Care2016;33(8):782‐90. [DOI: 10.1177/1049909116630266] ">Mikan 2016</a>). A recent systematic review has shown that approximately 40% of patients suffered pain after curative treatment, 55% during cancer treatment, and 66% in advanced disease. Pain related to cancer is frequently described as distressing or intolerable by more than one‐third of patients (<a href="./references#CD012638-bbs2-0051" title="BreivikH , ChernyN , CollettB , DeConnoF , FilbetM , FoubertAJ , et al. Cancer‐related pain: a pan‐European survey of prevalence, treatment, and patient attitudes. Annals of Oncology2009;20(8):1420‐33. [DOI: 10.1093/annonc/mdp001] ">Breivik 2009</a>; <a href="./references#CD012638-bbs2-0122" title="Van denBeuken‐van EverdingenMHJ , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51:1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">Van den Beuken‐van Everdingen 2016</a>). </p> <p>Cancer pain can be the result of the cancer itself, interventions to treat the cancer, and sometimes other underlying pains. Cancer‐related pain is a mosaic of different types of pain generated through different mechanisms. The biology of pain from bone metastasis may well differ from pain due to obstruction of a viscus (an internal organ) or invasion of soft tissue, resulting in differences in responsiveness to analgesics that act via different mechanisms. Prevalence of pain is also linked to cancer type, with head and neck cancer showing the highest prevalence. Age also has an impact, with younger patients experiencing more pain (<a href="./references#CD012638-bbs2-0111" title="PrommerEE . Pharmacological management of cancer‐related pain. Cancer Control2015;22(4):412‐25. [PUBMED: 26678968] ">Prommer 2015</a>). For this review, we will not consider postsurgical pain or specific neuropathic pain conditions. </p> <p>The current World Health Organization (WHO) cancer pain ladder for adults recommends the use of oral non‐opioid analgesics, including NSAIDs, as the first step on the ladder, with or without an adjuvant (<a href="./references#CD012638-bbs2-0125" title="Anonymous . WHO analgesic ladder. who.int/cancer/palliative/painladder/en/ (accessed 7 February 2017). ">WHO 2017</a>). Non‐opioid analgesics are also to be used on the second and third steps, together with weak or strong opioids. The current National Institute for Health and Care Excellence (NICE) guidelines in the UK advises that non‐opioid analgesics alone be used for treating mild pain (0 to 3 on a 0 to 10 pain scale), together with a weak opioid such as codeine or tramadol for mild to moderate pain (3 to 6), and with a strong opioid such as morphine for severe pain (6 to 10) (<a href="./references#CD012638-bbs2-0107" title="National Institute for Health and Care Excellence. Palliative cancer care ‐ pain. cks.nice.org.uk/palliative‐cancer‐care‐pain (accessed 7 February 2017). ">NICE 2016</a>). Some authorities have suggested that the second step on the ladder could be removed, and replaced with low doses of strong opioids such as morphine (<a href="./references#CD012638-bbs2-0121" title="TwycrossR , WilcockA , HowardP . Palliative Care Formulary. PCF5. Nottingham: Palliativedrugs.com Ltd, 2014. [ISBN: 978‐0‐9552547‐9‐6] ">Twycross 2014</a>). </p> </section> <section id="CD012638-sec-0032"> <h3 class="title" id="CD012638-sec-0032">Description of the intervention</h3> <p>NSAIDs have been prescribed for pain and inflammation for more than 100 years. Salicylic acid and phenazone were produced in a synthetic process in the late 1870s, and salicylic acid, phenazone, and phenacetin were available for the treatment of pain, fever, and inflammation by the turn of the 20th century. The past 60 years has seen the introduction of paracetamol (which is probably a weak NSAID (<a href="./references#CD012638-bbs2-0083" title="HinzB , ChereminaO , BruneK . Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. Federation of American Societies for Experimental Biology Journal2008;22(2):383‐90. [DOI: 10.1096/fj.07‐8506com] ">Hinz 2008</a>)) followed by ibuprofen, diclofenac, and many others (<a href="./references#CD012638-bbs2-0053" title="BruneK , HinzB . The discovery and development of anti‐inflammatory drugs. Arthritis and Rheumatology2004;50(8):2391‐9. [DOI: 10.1002/art.20424] ">Brune 2004</a>). NSAIDs are used with the aim of providing anti‐inflammatory, antipyretic, and analgesic effects in acute and chronic conditions of pain and inflammation (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012382/full#CD012382-bbs2-0050" target="_blank">Dwivedi 2015</a>). </p> <p>NSAIDs are among the most commonly used analgesics, mostly by prescription for musculoskeletal problems (<a href="./references#CD012638-bbs2-0088" title="LaineL . Approaches to nonsteroidal anti‐inflammatory drug use in the high‐risk patient. Gastroenterology2001;120(3):594‐606. [DOI: 10.1053/gast.2001.21907] ">Laine 2001</a>) or fibromyalgia (<a href="./references#CD012638-bbs2-0084" title="HäuserW , JungE , Erbslöh‐MöllerB , GesmannM , Kühn‐BeckerH , PetermannF , et al. The German fibromyalgia consumer reports ‐ a cross‐sectional survey. BMC Musculoskeletal Disorders2012;13:74. [DOI: 10.1186/1471‐2474‐13‐74] ">Häuser 2012</a>; <a href="./references#CD012638-bbs2-0131" title="WolfeF , WalittBT , KatzRS , LeeYC , MichaudKD , HäuserW . Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain2014;17(4):581‐6. [DOI: 10.1002/j.1532‐2149.2012.00234.x] ">Wolfe 2014</a>), but also widely used without prescription (<a href="./references#CD012638-bbs2-0117" title="SheenCL , DillonJF , BatemanDN , SimpsonKJ , MacDonaldTM . Paracetamol pack size restriction: the impact on paracetamol poisoning and the over‐the‐counter supply of paracetamol, aspirin and ibuprofen.. Pharmacoepidemiology and Drug Safety2002;11(4):329‐31. [DOI: 10.1002/pds.701] ">Sheen 2002</a>). NSAIDs act by inhibiting the cyclooxygenases (COXs), which are catalysts in the synthesis of prostaglandin. The analgesic and anti‐inflammatory actions of NSAIDs are attributed to the inhibition of cyclooxygenase‐2 (COX‐2), while any anti‐platelet and adverse gastrointestinal effects are attributed to the inhibition of cyclooxygenase‐1 (COX‐1). Many traditional NSAIDs such as ibuprofen are non‐selective. </p> <p>COX‐2‐selective NSAIDs were therefore developed to reduce adverse gastrointestinal effects, but were later considered to increase the risk of myocardial infarction and stroke (<a href="./references#CD012638-bbs2-0058" title="Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of nonsteroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet2014;382(9894):769‐79. [DOI: 10.1016/S0140‐6736(13)60900‐9] ">CNT 2014</a>), and some drugs were withdrawn (<a href="./references#CD012638-bbs2-0072" title="European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf (accessed 7 February 2017). ">EMEA 2005</a>; <a href="./references#CD012638-bbs2-0075" title="Food , DrugAdministration . FDA Public Health Advisory: safety of Vioxx. fda.gov/drugs/drugSafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106274.htm (accessed 7 February 2017). ">FDA 2004</a>). Whether available drugs increase the risk of cardiovascular effects is a matter of dispute, with the randomised trial evidence pointing to some increased risk for many (<a href="./references#CD012638-bbs2-0058" title="Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of nonsteroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet2014;382(9894):769‐79. [DOI: 10.1016/S0140‐6736(13)60900‐9] ">CNT 2014</a>), while large‐scale observational studies can point to no increased risk or even a reduced risk of serious harm (<a href="./references#CD012638-bbs2-0089" title="MangoniAA , WoodmanRJ , GaganisP , GilbertAL , KnightsKM . Use of nonsteroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community. British Journal of Clinical Pharmacology2010;69(6):689‐700. [DOI: 10.1111/j.1365‐2125.2010.03627.x] ">Mangoni 2010</a>). There is a fine balance of benefits and risks (<a href="./references#CD012638-bbs2-0102" title="MooreRA , DerryS , SimonLS , EmeryP . Nonsteroidal anti‐inflammatory drugs, gastroprotection, and benefit‐risk. Pain Practice2014;14(4):378‐95. [DOI: 10.1111/papr.12100] ">Moore 2014b</a>). </p> </section> <section id="CD012638-sec-0033"> <h3 class="title" id="CD012638-sec-0033">How the intervention might work</h3> <p>Anti‐inflammatory, antipyretic, and analgesic effects of NSAIDs are based on the suppression of the COX‐1 and COX‐2 enzymes. By blocking the COX enzymes, vasodilation is reduced and inflammation relieved. Further, the synthesis of prostaglandins is blocked, leading to reduced pain (<a href="./references#CD012638-bbs2-0068" title="DwivediAK , GurjarV , KumarS , SinghN . Molecular basis for nonspecificity of nonsteroidal anti‐inflammatory drugs (NSAIDs). Drug Discovery Today2015;20(7):863‐73. [DOI: 10.1016/j.drudis.2015.03.004] ">Dwivedi 2015</a>). NSAIDs block the prostaglandin synthesis as do steroids, but have a different side‐effect profile to steroids. Conventional NSAIDs (aspirin, ibuprofen, diclofenac, indomethacin, naproxen, and piroxicam) block COX‐1 and COX‐2 enzymes to various degrees. Selective COX‐2 inhibiting NSAIDs (celecoxib, etoricoxib) inhibit the COX‐2 enzyme with a 5 to 50 fold selectivity (<a href="./references#CD012638-bbs2-0053" title="BruneK , HinzB . The discovery and development of anti‐inflammatory drugs. Arthritis and Rheumatology2004;50(8):2391‐9. [DOI: 10.1002/art.20424] ">Brune 2004</a>), and some conventional NSAIDs are selective for COX‐1 (aspirin, for instance). </p> <p>NSAIDs are responsible for anti‐platelet, gastrointestinal, cardiovascular, renal, and hepatotoxic side effects (<a href="./references#CD012638-bbs2-0054" title="BruneK , PatrignaniP . New insights into the use of currently available nonsteroidal anti‐inflammatory drugs. Journal of Pain Research2015;8:105‐18. [DOI: 10.2147/JPR.S75160] ">Brune 2015</a>). Gastrointestinal adverse events with NSAIDs are the result of blocking of the COX‐1 enzyme, leading to a reduction in mucosal prostaglandin synthesis and its protective effects. </p> <p>Because there is strong evidence for an important role for increased COX‐2 expression and prostaglandin‐E2 production in colorectal tumorigenesis, drugs that inhibit COX‐2 have been of interest in the potential chemoprevention and therapy of colorectal cancer (<a href="./references#CD012638-bbs2-0057" title="ChellS , PatsosHA , QualtroughD , H‐ZadehAM , HicksDJ , KaidiA , et al. Prospects in NSAID‐derived chemoprevention of colorectal cancer. Biochemical Society Transactions2005;33(Pt 4):667‐71. ">Chell 2005</a>; <a href="./references#CD012638-bbs2-0124" title="WenderRC . Aspirin and NSAID chemoprevention, gene‐environment interactions, and risk of colorectal cancer. JAMA2015;313(11):1111‐2. [DOI: 10.1001/jama.2015.1032] ">Wender 2015</a>). </p> </section> <section id="CD012638-sec-0034"> <h3 class="title" id="CD012638-sec-0034">Why it is important to do this review</h3> <p>A previous Cochrane review examined the evidence for NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (<a href="./references#CD012638-bbs2-0133" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>), with the last search date in 2005. There have been few subsequent systematic reviews of the evidence. Nabal and colleagues (<a href="./references#CD012638-bbs2-0105" title="NabalM , LibradaS , RedondoMJ , PigniA , BrunelliC , CaraceniA . The role of paracetamol and nonsteroidal anti‐inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliative Medicine2012;26(4):305‐12. [DOI: 10.1177/0269216311428528] ">Nabal 2012</a>) examined the evidence for combinations with opioids, finding little evidence. A review of paracetamol and NSAIDs concluded that the role of these non‐opioid drugs remains controversial (<a href="./references#CD012638-bbs2-0093" title="MercadanteS , GiarratanoA . The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Mercadante 2013</a>). </p> <p>The evidence of effectiveness of the WHO pain ladder for cancer has been examined several times in the past two decades. These studies report varying degrees of success, typically between 20% and 100% of people with cancer pain achieving good relief (<a href="./references#CD012638-bbs2-0048" title="Azevedo São Leão FerreiraK , KimuraM , Jacobsen TeixeiraM . The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?. Supportive Care in Cancer2006;14(11):1086‐93. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Azevedo São Leão Ferreira 2006</a>; <a href="./references#CD012638-bbs2-0056" title="CarlsonCL . Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. Journal of Pain Research2016;9:515‐34. [10.2147/JPR.S97759. eCollection 2016] ">Carlson 2016</a>; <a href="./references#CD012638-bbs2-0087" title="JadadAR , BrowmanGP . The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA1995;274(23):1870‐3. ">Jadad 1995</a>), with some suggesting that as many as 50% of people with cancer pain are undertreated (<a href="./references#CD012638-bbs2-0061" title="DeandreaS , MontanariM , MojaL , ApoloneG . Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology2008;19(12):1985‐91. [DOI: 10.1093/annonc/mdn419] ">Deandrea 2008</a>). </p> <p>In many countries, opioids are severely restricted, if available at all. This means that many people with cancer will have considerable pain and suffering unless non‐opioid analgesics can be used. This review was designed with the intention of informing policy makers such as the WHO on the possible utility of NSAIDs to treat cancer‐related pain. It is hoped that the review will inform patients and carers on the value or otherwise of NSAIDs in this context. </p> <p>Other relevant Cochrane reviews include an assessment of codeine alone and with paracetamol (<a href="./references#CD012638-bbs2-0118" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>), and an evaluation of tramadol alone and with paracetamol (<a href="./references#CD012638-bbs2-0130" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012508.pub2] ">Wiffen 2017b</a>). A number of other reviews have evaluated the evidence for opioids, including buprenorphine (<a href="./references#CD012638-bbs2-0115" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015a</a>), transdermal fentanyl (<a href="./references#CD012638-bbs2-0080" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>), hydromorphone (<a href="./references#CD012638-bbs2-0049" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>), morphine (<a href="./references#CD012638-bbs2-0128" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>), oxycodone (<a href="./references#CD012638-bbs2-0116" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015b</a>), and tapentadol (<a href="./references#CD012638-bbs2-0127" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>). </p> <p>The standards used to assess evidence in pain trials have changed substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy (<a href="./references#CD012638-bbs2-0100" title="MooreRA . What works for whom? Determining the efficacy and harm of treatments for pain. Pain2013;154 Suppl 1:S77‐86. [DOI: 10.1016/j.pain.2013.03.024] ">Moore 2013b</a>). The most important change is the move away from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) (<a href="./references#CD012638-bbs2-0069" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>; <a href="./references#CD012638-bbs2-0099" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). Pain intensity reduction of 50% or more correlates with improvements in comorbid symptoms, function, and quality of life generally (<a href="./references#CD012638-bbs2-0101" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014a</a>). These standards are set out in the PaPaS author and referee guidance for pain studies of the Cochrane Pain, Palliative and Supportive Care Group (<a href="./references#CD012638-bbs2-0109" title="CochranePain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 7 February 2017). ">PaPaS 2012</a>). </p> <p>Three additional issues potentially affect how evidence is evaluated.</p> <p>The first issue is study size and the overall amount of information available for analysis. There are issues over both random chance effects with small amounts of data, and potential bias in small studies, especially in pain (<a href="./references#CD012638-bbs2-0062" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartes 2013</a>; <a href="./references#CD012638-bbs2-0063" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012638-bbs2-0074" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the United States of America2017;114(14):3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD012638-bbs2-0095" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012638-bbs2-0106" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology2017;84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>; <a href="./references#CD012638-bbs2-0108" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>; <a href="./references#CD012638-bbs2-0119" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>). Cochrane reviews have been criticised for perhaps over‐emphasising results of underpowered studies or analyses (<a href="./references#CD012638-bbs2-0047" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012638-bbs2-0120" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). On the other hand, it may be unethical to ignore potentially important information from small studies or to randomise more participants if a meta‐analysis including small, existing studies provided conclusive evidence. In this review, we have therefore chosen to limit analyses to studies with a minimum of 25 participants per treatment group, which we believe has not been done previously. </p> <p>The second issue is that of study duration. Previous reviews have examined studies of any duration, even in some cases single‐dose studies, or studies lasting one day or less, often with intravenous or intramuscular formulations (<a href="./references#CD012638-bbs2-0133" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>; <a href="./references#CD012638-bbs2-0093" title="MercadanteS , GiarratanoA . The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Mercadante 2013</a>). While short‐term studies and non‐oral formulations may have some relevance in some circumstances, they have little relevance to the vast majority of people with cancer pain who will be treated with oral NSAIDs over weeks, months, or even years. We have therefore chosen to include only studies with five days' duration or longer. </p> <p>The third issue is that of comparators. Many cancer pain studies involve direct comparisons of one or more formulations of the same drug, as particularly noted for oral morphine (<a href="./references#CD012638-bbs2-0128" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). This type of design has limited importance in evaluating the analgesic contribution of a drug, if that is not already well established (<a href="./references#CD012638-bbs2-0091" title="McQuayHJ , MooreRA . Placebo. Postgraduate Medical Journal2005;81(953):155‐60. [DOI: 10.1136/pgmj.2004.024737] ">McQuay 2005</a>). For that reason, we have limited this review to the two comparators that speak to the efficacy of NSAIDs in cancer pain, namely the comparison of an NSAID versus placebo, and NSAID plus opioid versus the same dose of opioid alone. The latter comparison would be similar to methods used for determining dose‐response of analgesics in acute pain (<a href="./references#CD012638-bbs2-0092" title="McQuayHJ , MooreRA . Dose‐response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. British Journal of Clinical Pharmacology2007;63(3):271‐8. [DOI: 10.1111/j.1365‐2125.2006.02723.x] ">McQuay 2007</a>), or caffeine as an analgesic adjuvant in acute pain (<a href="./references#CD012638-bbs2-0065" title="DerryCJ , DerryS , MooreRA . Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD009281.pub3] ">Derry 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012638-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012638-sec-0035"></div> <p>To assess the efficacy of oral NSAIDs for cancer pain in adults, and the adverse events reported during their use in clinical trials. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012638-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012638-sec-0036"></div> <section id="CD012638-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012638-sec-0038"> <h4 class="title">Types of studies</h4> <p>To be included, studies had to:</p> <p> <ul id="CD012638-list-0001"> <li> <p>be randomised (described as 'randomised' anywhere in the manuscript);</p> </li> <li> <p>ideally be double‐blind, but we included single‐blind or open studies because we expected there to be a limited literature on this important topic, and we wanted to be as inclusive as possible; </p> </li> <li> <p>include a minimum of 25 participants per treatment arm; for cross‐over studies this meant a minimum of 25 participants at the initial randomisation. </p> </li> <li> <p>have a study duration of at least five days of continuous treatment, with outcomes reported at the end of that period. </p> </li> </ul> </p> <p>We excluded non‐randomised studies, studies of experimental pain, case reports and clinical observations. Studies had to be fully published or available as extended abstracts (e.g. from clinical trial websites); we excluded short (usually conference) abstracts as these are often unreliable (<a href="./references#CD012638-bbs2-0109" title="CochranePain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 7 February 2017). ">PaPaS 2012</a>). </p> <p>Because dipyrone is known to produce substantial (90% or greater) inhibition of COX‐1 and COX‐2 through its 4‐methyl‐amino‐antipyrine metabolite (<a href="./references#CD012638-bbs2-0082" title="HinzB , ChereminaO , BachmakovJ , RennerB , ZolkO , FrommMF , et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. Federation of American Societies for Experimental Biology Journal2007;21(10):2343‐51. [DOI: 10.1096/fj.06‐8061com] ">Hinz 2007</a>), we have included it in the list of NSAIDs. </p> </section> <section id="CD012638-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (18 years or older) with cancer pain of any intensity. We did not consider postsurgical pain or specific neuropathic pain conditions. </p> </section> <section id="CD012638-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Orally administered NSAID for cancer pain where the NSAID alone was compared with placebo or another analgesic (e.g. a different NSAID, paracetamol, or an opioid), or orally administered NSAID combined with an opioid compared with the same dose of opioid alone. </p> </section> <section id="CD012638-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>Pain had to be measured using a validated assessment tool. For pain intensity, for example, this could be a 100 mm visual analogue scale (VAS) or 11‐point numerical rating scale (no pain to worst pain imaginable), or a four‐point categorical scale (none, mild, moderate, severe); for pain relief, for example, it could be a 100 mm VAS (no relief to complete relief), or five‐point categorical scale (none, a little, some, a lot, complete or words to that effect). Measures of 30% or greater (moderate) and 50% or greater (substantial) reduction of pain over baseline are recommended outcomes for chronic pain studies from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (<a href="./references#CD012638-bbs2-0069" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). </p> <p>A 30% or greater reduction of pain from baseline corresponds to much or very much improved on Patient Global Impression of Change (PGIC), and 50% or greater reduction corresponds to very much or completely improved. We would also use results equivalent to no pain or mild pain, because these are also outcomes acceptable to people with various types of pain (<a href="./references#CD012638-bbs2-0099" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> <section id="CD012638-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012638-list-0002"> <li> <p>Number of participants with pain reduction of 50% or greater from baseline.</p> </li> <li> <p>Number of participants with pain reduction of 30% or greater from baseline.</p> </li> <li> <p>Number of participants with pain no worse than mild (<a href="./references#CD012638-bbs2-0099" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> </li> <li> <p>Number of participants with PGIC of much improved or very much improved (or equivalent wording). </p> </li> </ul> </p> </section> <section id="CD012638-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012638-list-0003"> <li> <p>Quality of life.</p> </li> <li> <p>Use of rescue medication.</p> </li> <li> <p>Participant satisfaction or preference.</p> </li> <li> <p>Serious adverse events, including death.</p> </li> <li> <p>Other adverse events, particularly reports of effects of treatment on somnolence, appetite, or thirst, because these are of particular interest (<a href="./references#CD012638-bbs2-0126" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>). </p> </li> <li> <p>Withdrawals due to lack of efficacy, adverse events, or any cause.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012638-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012638-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases, without language or date restrictions.</p> <p> <ul id="CD012638-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (via CRSO) on 4 April 2017. </p> </li> <li> <p>MEDLINE (via Ovid) from 1946 to 4 April 2017.</p> </li> <li> <p>Embase (via Ovid) from 1974 to 4 April 2017.</p> </li> </ul> </p> <p>We used a combination of MeSH (or equivalent) and text word terms and tailored search strategies to individual databases. The search strategy for CENTRAL, MEDLINE, and Embase are in <a href="./appendices#CD012638-sec-0108">Appendix 1</a>, <a href="./appendices#CD012638-sec-0109">Appendix 2</a>, and <a href="./appendices#CD012638-sec-0110">Appendix 3</a>, respectively. </p> </section> <section id="CD012638-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched the metaRegister of controlled trials in ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) for ongoing and unpublished trials. In addition, we checked reference lists of reviews and retrieved articles for additional studies and performed citation searches on key articles. We did not contact authors for additional information. </p> </section> </section> <section id="CD012638-sec-0047"> <h3 class="title" id="CD012638-sec-0047">Data collection and analysis</h3> <section id="CD012638-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RAM, SD) independently read the abstract of each study identified by the search, eliminated studies that clearly did not satisfy inclusion criteria, and obtained full copies of the remaining studies. Two review authors (RAM, SD) read these studies independently to select relevant studies for inclusion. In the event of disagreement, a third review author (PW) was available to adjudicate. We did not anonymise the studies before assessment. We have included a PRISMA flow chart in the review to show the status of identified studies as recommended in Section 11.2.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012638-bbs2-0081" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We included studies in the review, irrespective of whether measured outcome data were reported in a 'usable' way. </p> </section> <section id="CD012638-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RAM, SD) independently extracted data using a standard form and checked for agreement before entry into Review Manager (RevMan) (<a href="./references#CD012638-bbs2-0113" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We included information about the number of participants treated and demographic details, type of cancer, drug and dosing regimen, study design (placebo or active control) and methods, study duration and follow‐up, analgesic outcome measures and results, withdrawals and adverse events. We collated multiple reports of the same study, so that each study rather than each report is the unit of interest in the review. We collected characteristics of the included studies in sufficient detail to complete a <a href="./references#CD012638-sec-0124" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD012638-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RAM, SD) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8, <a href="http://archie.cochrane.org/sections/documents/view?version=z1701111321125315331878489805618%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We completed a 'Risk of bias' table for each included study, using the 'Risk of bias' tool in RevMan (<a href="http://archie.cochrane.org/sections/documents/view?version=z1701111321125315331878489805618%26format=REVMAN#REF-RevMan-2014" target="_blank">RevMan 2014</a>). </p> <p>We assessed the following for each study.</p> <p> <ul id="CD012638-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated); high risk of bias where study did not conceal allocation (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved); high risk of bias (study participants or personnel, or both, not blinded). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received as: low risk of bias (study had a clear statement that outcome assessors were unaware of treatment allocation, and ideally described how this was achieved); unclear risk of bias (study stated that outcome assessors were blind to treatment allocation but lacked a clear statement on how it was achieved); high risk of bias (outcome assessment not blinded). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (fewer than 10% of participants did not complete the study or used ‘baseline observation carried forward’ analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. We assessed the methods used to deal with incomplete data as: low risk of reporting bias if the study protocol was available and all of the study’s prespecified (primary and secondary) outcomes that were of interest in the review were reported in the pre‐specified way, or if the study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon); high risk of reporting bias if not all of the study’s pre‐specified primary outcomes were reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study; and unclear risk of bias risk’ of bias if insufficient information is available to permit judgement of ‘Low risk’ or ‘High risk’. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size (<a href="./references#CD012638-bbs2-0062" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartes 2013</a>; <a href="./references#CD012638-bbs2-0063" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012638-bbs2-0095" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012638-bbs2-0108" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>; <a href="./references#CD012638-bbs2-0119" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>)). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD012638-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to use dichotomous data to calculate risk difference (RD) or risk ratio (RR) with 95% confidence intervals (CIs) using a fixed‐effect model, and calculate numbers needed to treat for one additional beneficial outcome (NNT) as the reciprocal of the absolute risk reduction (<a href="./references#CD012638-bbs2-0090" title="McQuayH , MooreA . An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2] ">McQuay 1998</a>). For unwanted effects, the number needed to treat (NNT) becomes the number needed to treat for one additional harmful outcome (NNH), and is calculated similarly. </p> <p>We planned to use the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD012638-list-0006"> <li> <p>When significantly fewer adverse outcomes occurred with NSAIDs than with control (placebo or active control), we used the term number needed to treat to prevent one event (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occurred with NSAIDs compared with control (placebo or active control) we used the term number needed to treat for an additional harmful outcome or cause one event (NNH). </p> </li> </ul> </p> <p>We did not plan to use continuous data for the primary outcome because it is inappropriate where there is an underlying skewed distribution, as is usually the case with analgesic response. </p> </section> <section id="CD012638-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the individual participant.</p> </section> <section id="CD012638-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use intention‐to‐treat (ITT) analyses: participants who were randomised, took the study medication, and gave a minimum of one post‐baseline assessment. We have reported per‐protocol data in the absence of ITT data. </p> </section> <section id="CD012638-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess statistical heterogeneity using L'Abbé plots, a visual method for assessing differences in results of individual studies (<a href="http://archie.cochrane.org/sections/documents/view?version=z1701111321125315331878489805618%26format=REVMAN#REF-L_x0027_Abb_x00e9_-1987" target="_blank">L'Abbé 1987</a>), and by use of the I<sup>2</sup> statistic. We anticipated that there could be an effect of differences between participants, environment (inpatient versus outpatient), and outcome measures. We planned to explore these with subgroup and sensitivity analyses where there were sufficient data, recognising the difficulties of assessing heterogeneity with small numbers of small studies (<a href="./references#CD012638-bbs2-0076" title="GavaghanDJ , MooreRA , McQuayHJ . An evaluation of homogeneity tests in meta‐analyses in pain using simulations of individual patient data. Pain2000;85(3):415‐24. ">Gavaghan 2000</a>; <a href="./references#CD012638-bbs2-0086" title="IntHoutJ , IoannidisJP , BormGF , GoemanJJ . Small studies are more heterogeneous than large ones: a meta‐meta‐analysis. Journal of Clinical Epidemiology2015;68:860‐9. [DOI: 10.1016/j.jclinepi.2015.03.017] ">IntHout 2015</a>). In the event, there were insufficient data to assess heterogeneity. </p> </section> <section id="CD012638-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use dichotomous data of known utility (<a href="./references#CD012638-bbs2-0097" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] ">Moore 2010a</a>; <a href="./references#CD012638-bbs2-0099" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). The review would not depend on what authors of the original studies chose to report or not. </p> <p>We planned to undertake an assessment of publication bias if there were sufficient data for meta‐analysis, using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher) (<a href="./references#CD012638-bbs2-0096" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). In the event, there were insufficient data to assess publication bias. </p> </section> <section id="CD012638-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake a quantitative synthesis and present data in forest plots if there were sufficient data. In the event of substantial clinical heterogeneity, we would switch off the totals in the forest plots. </p> <p> <ul id="CD012638-list-0007"> <li> <p>We would undertake a meta‐analysis only if participants, interventions, comparisons, and outcomes were judged to be sufficiently similar to ensure an answer that is clinically meaningful. </p> </li> <li> <p>We would undertake a meta‐analysis only where there were data from at least two studies and 200 participants for analysis. </p> </li> <li> <p>We planned to use RevMan for meta‐analysis (<a href="./references#CD012638-bbs2-0113" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and Excel for NNT and NNH. </p> </li> </ul> </p> <p>In the event, there were insufficient data for pooling of data for any outcome.</p> <section id="CD012638-sec-0057"> <h5 class="title">Quality of the evidence</h5> <p>We used the GRADE system to assess the quality of the evidence related to the key outcomes listed in <a href="#CD012638-sec-0041">Types of outcome measures</a>, as appropriate (<a href="./appendices#CD012638-sec-0111">Appendix 4</a>). Two review authors (RAM, SD) independently rated the quality of each outcome. </p> <p>We paid particular attention to inconsistency, where point estimates vary widely across studies or confidence intervals (CIs) of studies show minimal or no overlap (<a href="./references#CD012638-bbs2-0077" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Cinical Epidemiology2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] ">Guyatt 2011</a>), and to the potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD012638-bbs2-0096" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). </p> <p>In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD012638-bbs2-0078" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66:151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] ">Guyatt 2013a</a>). For example, if there are so few data that the results are highly susceptible to the random play of chance, or if a study uses last observation carried forward (LOCF) imputation in circumstances where there are substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we have reported the level of evidence as very low quality (<a href="./references#CD012638-bbs2-0079" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables ‐ binary outcomes. Journal of Clinical Epidemiology2013;66:158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] ">Guyatt 2013b</a>). </p> <p>In addition, we are aware that many Cochrane reviews are based largely or wholly on small underpowered studies, and that there is a danger of making conclusive assessments of evidence based on inadequate information (<a href="./references#CD012638-bbs2-0047" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012638-bbs2-0052" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD012638-bbs2-0114" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD012638-bbs2-0120" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). </p> </section> <section id="CD012638-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We have included a 'Summary of findings' table as set out in the Pain, Palliative and Supportive Care Review Group author guide (<a href="./references#CD012638-bbs2-0109" title="CochranePain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 7 February 2017). ">PaPaS 2012</a>) and recommended in Chapter 4.6.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012638-bbs2-0081" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We present the main findings in a simple tabular format, to include key information concerning the quality of evidence, the magnitude of effect of the interventions examined, the sum of available data on the outcomes of at least 30% and at least 50% pain relief, PGIC much or very much improved, adverse events, and serious adverse events. In addition, we have also included other measures of efficacy or harm (quality of life or well‐being at end of treatment, use of rescue medication, patient satisfaction or preference, withdrawals, and death). </p> <p>For the 'Summary of findings' table we used the following descriptors for levels of evidence (<a href="./references#CD012638-bbs2-0073" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 7 February 2017). ">EPOC 2015</a>). </p> <p><b>High:</b> This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low. </p> <p><b>Moderate:</b> This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate. </p> <p><b>Low:</b> This research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high. </p> <p><b>Very low:</b> This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </section> </section> <section id="CD012638-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned several possible subgroup analyses, depending on the availability of data.</p> <p> <ul id="CD012638-list-0008"> <li> <p>Because we expected that many studies would have a cross‐over design that could impede meta‐analysis (<a href="./references#CD012638-bbs2-0071" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>), we planned to examine cross‐over and parallel‐group designs separately. </p> </li> <li> <p>We planned to investigate whether subgroup analysis by individual drug or dose was possible. </p> </li> <li> <p>We planned to analyse separately studies with NSAID alone, and NSAID combined with opioid. We anticipated that these studies might also reflect different levels of initial pain intensity. </p> </li> </ul> </p> <p>We planned no other subgroup analyses because the data were expected to be sparse, with small numbers of small trials. In the event, there were insufficient data for any subgroup analysis. </p> </section> <section id="CD012638-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan any sensitivity analyses because the data were expected to be sparse, with small numbers of small trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012638-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012638-sec-0061"></div> <section id="CD012638-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD012638-sec-0063"> <h4 class="title">Results of the search</h4> <p>Searches identified 548 articles in CENTRAL, 1736 articles in MEDLINE, 2529 articles in Embase, and no additional relevant reports in clinical trial registries. We reassessed all studies included in the earlier review (<a href="./references#CD012638-bbs2-0133" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>). After screening and assessment of relevant full texts, we included 11 studies and excluded 35 studies (<a href="#CD012638-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012638-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012638-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_n/nCD012638-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012638-sec-0064"> <h4 class="title">Included studies</h4> <p>We included 11 studies, all of which were randomised <a href="./references#CD012638-bbs2-0001" title="CarlsonRW , BorrisonRA , SherHB , EisenbergPD , MowryPA , WolinEM . A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy1990;10(3):211‐6. [DOI: 10.1002/j.1875‐9114.1990.tb02577.x] ">Carlson 1990</a>; <a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a>; <a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a>; <a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a>; <a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a>; <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>; <a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a>; <a href="./references#CD012638-bbs2-0008" title="ToscaniF , PivaL , CorliO , GallucciM , SperanzaR , TamburiniM , et al. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung1994;44(4):550‐4. [PUBMED: 8011010] ">Toscani 1994</a>; <a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a>; <a href="./references#CD012638-bbs2-0010" title="VentafriddaV , ToscaniF , TamburiniM , CorliO , GallucciM , GottliebA , et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung1990;40(10):1132‐4. [PUBMED: 2291751] ">Ventafrida 1990a</a>; <a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a>). Two were not in the earlier review (<a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a>; <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>). Eight studies were double‐blind, two were single‐blind, and one was open‐label. None had a placebo only control. They initially randomised 949 participants, although not all contributed to outcomes. </p> <p>Three studies used a cross‐over design with treatment periods of seven days (<a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a>; <a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a>; <a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a>). <a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a> specified a 12‐hour washout between treatment phases, but there was no washout reported in the other two studies. Eight studies used a parallel‐group design, with treatment periods mostly between seven and 14 days, and one study (primarily investigating depression) lasting six weeks. </p> <p>No included study compared an NSAID with placebo, or compared an NSAID plus opioid with the same dose of opioid alone. </p> <p>Nine studies included treatment arms comparing one NSAID with a different NSAID (<a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a>; <a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a>; <a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a>; <a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a>; <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>; <a href="./references#CD012638-bbs2-0008" title="ToscaniF , PivaL , CorliO , GallucciM , SperanzaR , TamburiniM , et al. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung1994;44(4):550‐4. [PUBMED: 8011010] ">Toscani 1994</a>; <a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a>; <a href="./references#CD012638-bbs2-0010" title="VentafriddaV , ToscaniF , TamburiniM , CorliO , GallucciM , GottliebA , et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung1990;40(10):1132‐4. [PUBMED: 2291751] ">Ventafrida 1990a</a>; <a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a>), one of which was reported in three articles (<a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a>). Three studies compared an NSAID with an opioid (morphine; <a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a>), or an oral opioid combination (paracetamol plus codeine; <a href="./references#CD012638-bbs2-0001" title="CarlsonRW , BorrisonRA , SherHB , EisenbergPD , MowryPA , WolinEM . A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy1990;10(3):211‐6. [DOI: 10.1002/j.1875‐9114.1990.tb02577.x] ">Carlson 1990</a>, and aspirin plus codeine; <a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a>). </p> <p>Ten studies included both men and women, with a slight preponderance of men (60% overall). These studies each included participants with various types of cancer, except one that exclusively enrolled participants with bone cancer (<a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>). The other study included women with breast cancer (<a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a>). Where reported, the mean age was 52 to 70 years (age range 30 to 89 years). </p> <p>Most studies required participants to have moderate or severe pain levels at study entry, or reported baseline pain levels of at least moderate intensity. <a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a> required mild to moderate pain as an entry criterion, and reported mean baseline levels of 60 (± 7)/100. <a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a> recruited participants who "needed analgesic treatment according to the first step of WHO scale" and reported a mean baseline Integrated Pain Score of 40 to 50, which equates to at least moderate pain (<a href="./references#CD012638-bbs2-0060" title="DeConnoF , CaraceniA , GambaA , MarianiL , AbbattistaA , BrunelliC , et al. Pain measurement in cancer patients: a comparison of six methods. Pain1994;57(2):161‐6. [DOI: 10.1016/0304‐3959(94)90219‐4] ">De Conno 1994</a>). <a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a> reported only changes in pain levels, not absolute values. </p> <p>Doses of NSAIDs used were within recommended dosing schedules, and doses of oral morphine were 60 mg to 180 mg daily (<a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a>), and of oral codeine in combination with a non‐opioid were 160 mg or 240 mg daily (<a href="./references#CD012638-bbs2-0001" title="CarlsonRW , BorrisonRA , SherHB , EisenbergPD , MowryPA , WolinEM . A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy1990;10(3):211‐6. [DOI: 10.1002/j.1875‐9114.1990.tb02577.x] ">Carlson 1990</a>; <a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a>). </p> <p>Further details are in the <a href="./references#CD012638-sec-0124" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD012638-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded 35 studies, 31 of which were included in the earlier review (<a href="./references#CD012638-bbs2-0012" title="BjörkmanR , UllmanA , HednerJ . Morphine‐sparing effect of diclofenac in cancer pain. European Journal of Clinical Pharmacology1993;44(1):1‐5. [DOI: 10.1007/BF00315271] ">Bjorkman 1993</a>; <a href="./references#CD012638-bbs2-0013" title="BosekV , MiguelR . Comparison of morphine and ketorolac for intravenous patient‐controlled analgesia in postoperative cancer patients. Clinical Journal of Pain1994;10(4):314‐8. [PUBMED: 7858362] ">Bosek 1994</a>; <a href="./references#CD012638-bbs2-0014" title="CharyS , GoughnourBR , MoulinDE , ThorpeWR , HarsanyiZ , DarkeAC . The dose‐response relationship of controlled‐release codeine (Codeine Contin) in chronic cancer pain. Journal of Pain and Symptom Management1994;9(6):363‐71. [DOI: 10.1016/0885‐3924(94)90173‐2] ">Chary 1994</a>; <a href="./references#CD012638-bbs2-0016" title="CorliO , CozzolinoA , ScaricabarozziI . Nimesulide and diclofenac in the control of cancer‐related pain. Comparison between oral and rectal administration. Drugs1993;46 (Suppl 1):152‐5. [PUBMED: 7506158] ">Corli 1993</a>; <a href="./references#CD012638-bbs2-0017" title="DellemijnPLI , VerbiestHBC , vanVlietJJ , RoosPJ , VechtCJ . Medical therapy of malignant nerve pain. A randomized double‐blind explanatory trial with naproxen versus slow‐release morphine. European Journal of Cancer1994;30A(9):1244‐50. [PUBMED: 7999406] DellemijnPLI , VerbiestHBC , vanVlietJJ , vanPuttenWLJ , VechtCJ . Nociceptive nerve pain in cancer: a double‐blind study with naproxen versus slow‐release morphine. Clinical Neurology and Neurosurgery1993;95:331. [CENTRAL: CN‐00364074] ">Dellemijn 1994</a>; <a href="./references#CD012638-bbs2-0019" title="EstapéJ , ViñolasN , GonzálezB , InglésF , BofillT , GuzmánMC , et al. Ketorolac, a new non‐opioid analgesic: a double‐blind trial versus pentazocine in cancer pain. Journal of International Medical Research1990;18(4):298‐304. [DOI: 10.1177/030006059001800406] ">Estapé 1990</a>; <a href="./references#CD012638-bbs2-0020" title="Ferrer‐BrechnerT , GanzP . Combination therapy with ibuprofen and methadone for chronic cancer pain. American Journal of Medicine1984;77(1A):78‐83. [DOI: 10.1016/S0002‐9343(84)80023‐6] ">Ferrer‐Brechner 1984</a>; <a href="./references#CD012638-bbs2-0021" title="FrankendalB . Clinical testing of a new analgesic combination on cancer patients in chronic pain [Klinisk provning av ny analgetikakombination pa cancerpatienter med kroniska smartor]. Lakartidningen1973;70(10):949‐51. [PUBMED: 4572816] ">Frankendal 1973</a>; <a href="./references#CD012638-bbs2-0022" title="JohnsonJR , MillerAJ . The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study. Palliative Medicine1994;8(2):129‐35. [DOI: 10.1177/026921639400800206] ">Johnson 1994</a>; <a href="./references#CD012638-bbs2-0023" title="LaurettiGR , LimaIC , ReisMP , PradoWA , PereiraNL . Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology1999;90(6):1528‐33. [PUBMED: 10360847] ">Lauretti 1999</a>; <a href="./references#CD012638-bbs2-0024" title="LevickS , JacobsC , LoukasDF , GordonDH , MeyskensFL , UhmK . Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain1988;35(3):253‐8. [DOI: 10.1016/0304‐3959(88)90134‐0] ">Levick 1988</a>; <a href="./references#CD012638-bbs2-0025" title="LomenPL , SamalBA , LambornKR , SattlerLP , CramptonSL . Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer. American Journal of Medicine1986;80(3A):83‐7. [DOI: 10.1016/0002‐9343(86)90118‐X] ">Lomen 1986</a>; <a href="./references#CD012638-bbs2-0026" title="MartinoG , VentafriddaV , PariniJ , EmanueliA . A controlled study on the analgesic activity of indoprofen inpatients with cancer pain. In: BonicaJJ , Albe‐FessardD editor(s). Pharmacological Agents in Chronic Pain, Advances in Pain Research and Therapy. Vol. 1, New York: Raven Press, 1976:573‐8. ">Martino 1976</a>; <a href="./references#CD012638-bbs2-0028" title="MinottiV , BettiM , CiccareseG , FumiG , TonatoM , DelFaveroA . A double‐blind study comparing two single‐dose regimens of ketorolac with diclofenac in pain due to cancer. Pharmacotherapy1998;18(3):504–8. [PUBMED: 9620101] ">Minotti 1998a</a>; <a href="./references#CD012638-bbs2-0029" title="MinottiV , DeAngelisV , RighettiE , CelaniMG , RossettiR , LupatelliM , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain1998;74(2‐3):133‐7. [PUBMED: 9520227] ">Minotti 1998b</a>; <a href="./references#CD012638-bbs2-0030" title="MoertelCG , AhmannDL , TaylorWF , SchwartauN . Aspirin and pancreatic cancer pain. Gastroenterology1871;60(4):552‐3. [PUBMED: 5573227] ">Moertel 1971</a>; <a href="./references#CD012638-bbs2-0031" title="MoertelCG , AhmannDL , TaylorWF , SchwartauN . Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA1974;229(1):55‐9. [DOI: 10.1001/jama.1974.03230390031020] ">Moertel 1974</a>; <a href="./references#CD012638-bbs2-0032" title="SacchettiG , CameraP , RossiAP , MartoniA , BruniG , PannutiF . Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer pain: a double‐blind, crossover trial. Drug Intelligence and Clinical Pharmacy1984;18(5):403‐6. [PUBMED: 6373214] ">Sacchetti 1984</a>; <a href="./references#CD012638-bbs2-0033" title="SaxenaA , AndleyM , GnanasekaranN . Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double‐blind study. Palliative Medicine1994;8(3):223‐9. [DOI: 10.1177/026921639400800306] ">Saxena 1994</a>; <a href="./references#CD012638-bbs2-0035" title="StambaughJ , DrewJ . A double‐blind parallel evaluation of the efficacy and safety of a single dose of ketoprofen in cancer pain. Journal of Clinical Pharmacology1988;28(12 (Suppl)):S34‐9. [DOI: 10.1002/j.1552‐4604.1988.tb05975.x] ">Stambaugh 1988a</a>; <a href="./references#CD012638-bbs2-0036" title="StambaughJEJr , DrewJ . The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clinical Pharmacology and Therapeutics1988;44(6):665‐9. [DOI: 10.1038/clpt.1988.209] ">Stambaugh 1988b</a>; <a href="./references#CD012638-bbs2-0037" title="StaquetMJ . A double‐blind study with placebo control of intramuscular ketorolac tromethamine in the treatment of cancer pain. Journal of Clinical Pharmacology1989;29(11):1031‐6. [DOI: 10.1002/j.1552‐4604.1989.tb03274.x] ">Staquet 1989</a>; <a href="./references#CD012638-bbs2-0038" title="StaquetM , RenaudA . Double‐blind, randomized trial of piroxicam and codeine in cancer pain. Current Therapeutic Research1993;53(4):435‐9. ">Staquet 1993</a>; <a href="./references#CD012638-bbs2-0039" title="StrobelVE . Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac‐Na [Medikamentose Therapie beistarken Tumorschmerzen. Vergleichsstudie eines neuen Kombinationspraparats versus Diclofenac–Na]. Fortschritteder Medizin1992;110(22):411‐4. ">Strobel 1992</a>; <a href="./references#CD012638-bbs2-0040" title="SunshineA , OlsonNZ . Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain. Journal of Clinical Pharmacology1988;28 (12 Suppl):S47–S54. [DOI: 10.1002/j.1552‐4604.1988.tb05977.x] ">Sunshine 1988</a>; <a href="./references#CD012638-bbs2-0041" title="TonachellaR , CurcioC , GrossiE . Diclofenac sodium in cancer pain: A double‐blind within‐patients comparison with pentazocine. Current Therapeutic Research1985;37(6):1130‐3. ">Tonachella 1985</a>; <a href="./references#CD012638-bbs2-0042" title="VentafriddaV , MartinoG , MandelliV , EmanueliA . Indoprofen, a new analgesic and anti‐inflammatory drug in cancer pain. Clinical Pharmacology and Therapeutics1975;17(3):284‐9. [PUBMED: 47281] ">Ventafridda 1975</a>; <a href="./references#CD012638-bbs2-0043" title="VentafriddaV , DeConnoF , PaneraiAE , MarescaV , MonzaGC , RipamontiC . Non‐steroidal anti‐inflammatory drugs as the first step in cancer pain therapy: double‐blind, within‐patient study comparing nine drugs. Journal of International Medical Research1990;18(1):21‐9. [PUBMED: 2185963] ">Ventafridda 1990b</a>; <a href="./references#CD012638-bbs2-0044" title="WeingartWA , SorknessCA , EarhartRH . Analgesia with oral narcotics and added ibuprofen in cancer patients. Clinical Pharmacy1985;4(1):53‐8. [PUBMED: 3971683] ">Weingart 1985</a>; <a href="./references#CD012638-bbs2-0045" title="WoolC , PrandoniP , PolistenaP , RuolA . Ketorolac suppositories in the treatment of neoplastic pain: A randomized clinical trial versus diclofenac. Current Therapeutic Research1991;49(5):854–61. ">Wool 1991</a>; <a href="./references#CD012638-bbs2-0046" title="YalínS , GüllüI , TekuzmanG , SavasC . Ketorolac tromethamine in cancer pain. Acta Oncologica1997;36(2):231‐2. [DOI: 10.3109/02841869709109238] ">Yalcin 1997</a>), and four were newly identified (<a href="./references#CD012638-bbs2-0015" title="ChenY , ZhuW , LiangH , WuG . The analgesic effect of ibuprofen‐codeine sustained release tablets on postoperative and cancer pain. Chinese Journal of Clinical Rehabilitation2003;7(8):1290‐1. [CENTRAL: CN‐01305289] ">Chen 2003</a>; <a href="./references#CD012638-bbs2-0018" title="Duarte SouzaJF , LajoloPP , PinczowskiH , delGiglioA . Adjunct dipyrone in association with oral morphine for cancer‐related pain: the sooner the better. Supportive Care in Cancer2007;15(11):1319‐23. [DOI: 10.1007/s00520‐007‐0327‐7] ">Dutre Souza 2007</a>; <a href="./references#CD012638-bbs2-0027" title="MercadanteS , FulfaroF , CasuccioA . A randomised controlled study on the use of anti‐inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose‐escalation and a pharmacoeconomic analysis. European Journal of Cancer2002;38(10):1358‐63. [DOI: 10.1016/S0959‐8049(02)00102‐8] ">Mercadante 2002</a>; <a href="./references#CD012638-bbs2-0034" title="ShenW , ChenQ . The efficacy and tolerability of lornoxicam in treatment of pain in metastatic carcinoma of bone. Chinese Journal of New Drugs2003;12(7):561‐3. [CENTRAL: CN‐00495555] ">Shen 2003</a>). </p> <p>We excluded studies because the treatment duration was less than five days (20), they had fewer than 25 participants per treatment arm (12), or used a non‐oral route of administration (3). </p> <p>Other studies had been excluded from the earlier review because the drug had been discontinued due to serious adverse events, and we did not consider these for inclusion. </p> </section> </section> <section id="CD012638-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>Only two studies were without at least one high risk of bias (<a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a>; <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>; <a href="#CD012638-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012638-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD012638-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_n/nCD012638-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD012638-sec-0067"> <h4 class="title">Allocation</h4> <p>All studies were described as randomised, but only two adequately described the method used to generate the random sequence (<a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a>; <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>; low risk of bias). One study adequately described how the allocation of the sequence was concealed (<a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a>; low risk of bias). </p> </section> <section id="CD012638-sec-0068"> <h4 class="title">Blinding</h4> <p>We judged three studies at high risk of bias for blinding because one was open‐label (<a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a>), and two were single‐blind (<a href="./references#CD012638-bbs2-0008" title="ToscaniF , PivaL , CorliO , GallucciM , SperanzaR , TamburiniM , et al. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung1994;44(4):550‐4. [PUBMED: 8011010] ">Toscani 1994</a>; <a href="./references#CD012638-bbs2-0010" title="VentafriddaV , ToscaniF , TamburiniM , CorliO , GallucciM , GottliebA , et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung1990;40(10):1132‐4. [PUBMED: 2291751] ">Ventafrida 1990a</a>). Two studies did not adequately describe the methods of blinding (<a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a>; <a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a>; unclear risk of bias), and the remainder we judged at low risk. </p> </section> <section id="CD012638-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>We judged three studies at high risk of bias for incomplete outcome data because they did not report how withdrawals were handled in a situation where there were very high levels of attrition (<a href="./references#CD012638-bbs2-0001" title="CarlsonRW , BorrisonRA , SherHB , EisenbergPD , MowryPA , WolinEM . A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy1990;10(3):211‐6. [DOI: 10.1002/j.1875‐9114.1990.tb02577.x] ">Carlson 1990</a>; <a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a>; <a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a>). We judged <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a> at low risk because it used and described an appropriate method of imputation. We judged the remaining studies at unclear risk because they did not adequately report on how withdrawals were handled in analyses. </p> </section> <section id="CD012638-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Although protocols were not available for any of the included studies, we judged all of the studies to be at low risk of bias because they reported the outcomes stated in their Methods sections. Outcomes reported frequently did not include the efficacy outcomes of interest to this review. </p> </section> <section id="CD012638-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>We judged seven studies at high risk of bias because they had fewer than 50 participants in each treatment arm. The remaining four studies had between 50 and 200 participants per treatment arm, but most groups included fewer than 60 participants and the largest included 72; not all of the participants contributed to outcomes. </p> </section> </section> <section id="CD012638-sec-0072"> <h3 class="title" id="CD012638-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD012638-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>A summary of results for efficacy outcomes in individual studies is available in <a href="./appendices#CD012638-sec-0112">Appendix 5</a>, and for rescue medication, adverse events and withdrawals in <a href="./appendices#CD012638-sec-0113">Appendix 6</a>. <a href="./full#CD012638-tbl-0001">summary of findings Table for the main comparison</a> includes several of the main outcomes. </p> <section id="CD012638-sec-0073"> <h4 class="title">Efficacy</h4> <p>No included study compared an NSAID with placebo, or compared an NSAID plus opioid with the same dose of opioid alone. </p> <section id="CD012638-sec-0074"> <h5 class="title">Primary outcomes</h5> <p>Few studies reported any of our primary outcomes: participants with pain reduction of at least 50%, and at least 30%, from baseline; participants with pain no worse than mild at the end of the treatment period; participants with PGIC of much improved or very much improved (or equivalent wording). </p> <section id="CD012638-sec-0075"> <h6 class="title">NSAID versus NSAID</h6> <p><a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a> defined a "responder" as a participant who experienced ≥ 50% reduction in pain intensity or had pain of &lt; 40/100 at the end of the study, but did not report this or any pain outcome for the intended 10 days of treatment. Non‐responders at two days were withdrawn from the study (pain intensity &gt; 40/100 at two days: 16/33 diclofenac and 14/33 nefopam), and withdrawal rates were typically above 60%. </p> <p><a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a> reported a Patient Global Evaluation of "moderate, good or complete" in 83/128 participants with ketorolac 30 mg daily and 74/129 with diclofenac 150 mg daily after seven days. We judged this equivalent to PGIC of much improved or very much improved (≥ moderate benefit). A Patient Global Evaluation of "good or complete" (≥ substantial benefit) was reported in 34/128 participants with ketorolac 30 mg daily and 33/129 with diclofenac 150 mg daily (26% response rate at seven days with NSAID). </p> <p><a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a> reported the number of participants with pain intensity &lt; 30/100 at the end of the study; 31/56 with dexketoprofen trometamol 100 mg daily, and 27/57 with ketorolac 40 mg daily. With NSAID, therefore, 58/113 (51%) participants had a pain intensity below 30/100 after seven days. </p> <p>There were insufficient data to compare one NSAID with another. We assessed this as very low‐quality evidence. </p> </section> <section id="CD012638-sec-0076"> <h6 class="title">NSAID versus opioid</h6> <p><a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a> defined a "responder" as a participant who experienced ≥ 50% reduction in pain intensity or had pain of &lt; 40/100 at the end of the study, but did not report this or any pain outcome for the intended 10 days of treatment. Non‐responders at two days were withdrawn from the study (pain intensity &gt; 40/100 at two days: 16/33 diclofenac, 14/33 nefopam, 10/33 aspirin plus codeine), and withdrawal rates were typically above 60%. </p> <p><a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a> reported the number of participants experiencing at least 50% improvement in pain at five days as 5/41 with dipyrone 3000 mg daily, 15/38 with dipyrone 6000 mg daily, and 10/42 with morphine 60 mg daily. In an overall rating of efficacy, the numbers reporting "good or excellent" (judged equivalent to PGIC of much improved or very much improved) were 16/41 with dipyrone 3000 mg daily, 17/38 with dipyrone 6000 mg daily, and 19/42 with morphine 60 mg daily (42% response rate at seven days with NSAID). The evaluation of pain improvement appeared to show a difference between the two doses of dipyrone (higher was better), but not between the higher dose of dipyrone and morphine. The evaluation of overall efficacy did not replicate this difference. </p> <p>There were insufficient data to compare one NSAID with an opioid. We assessed this as very low‐quality evidence. </p> </section> </section> <section id="CD012638-sec-0077"> <h5 class="title">Other pain outcomes</h5> <section id="CD012638-sec-0078"> <h6 class="title">NSAID versus NSAID</h6> <p><a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a> reported that in participants who completed two weeks of treatment (43/68), the mean Integrated Pain Score was reduced by 65% with nimesulide 400 mg daily and by 70% with naproxen 1000 mg daily. We estimate that the mean baseline Integrated Pain Score of 40 to 50 was equivalent to moderate pain, and the mean 14‐day score of approximately 15 was equivalent to mild pain (<a href="./references#CD012638-bbs2-0060" title="DeConnoF , CaraceniA , GambaA , MarianiL , AbbattistaA , BrunelliC , et al. Pain measurement in cancer patients: a comparison of six methods. Pain1994;57(2):161‐6. [DOI: 10.1016/0304‐3959(94)90219‐4] ">De Conno 1994</a>). It seems likely that most participants who could tolerate treatment had no worse than mild pain at 14 days. </p> <p><a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a> reported a physician assessment of therapeutic efficacy of very good in 1/33 (3%) participants with diclofenac and 3/33 (10%) with nefopam. </p> <p><a href="./references#CD012638-bbs2-0004" title="MohammadinejadP , AryaP , EsfandbodM , KavianiA , NajafiM , KashaniL , et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] ">Mohammadinejad 2015</a> reported that mean pain was reduced from about 60/100 to about 45/100 after six weeks with both celecoxib 400 mg daily and diclofenac 100 mg daily. It is likely that most participants still had moderate pain levels. </p> <p><a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a> did not report baseline pain levels, but results suggest that pain was reduced by an average of about 15/100 with both naproxen 1000 mg daily and aspirin 3600 mg daily, with very large standard deviations. </p> <p><a href="./references#CD012638-bbs2-0010" title="VentafriddaV , ToscaniF , TamburiniM , CorliO , GallucciM , GottliebA , et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung1990;40(10):1132‐4. [PUBMED: 2291751] ">Ventafrida 1990a</a> reported that the mean Integrated Pain Score decreased by about 25 points (&gt; halved) in both groups, to 16 with naproxen sodium 1100 mg daily and 17 with diclofenac sodium 200 mg daily. This probably equates to moderate pain reduced to mild pain for most participants as the mean integrated pain score for weeks one and two was equivalent to all‐day slight pain or below (score of 1 for 24 hours = 24). </p> <p><a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a> reported a mean reduction in pain intensity of 4.7/10 with diflunisal 1000 mg daily and 3.3/10 with dipyrone 1500 mg daily, but with large standard deviations. </p> <p>These results using mean data for the most part indicate that NSAIDs reduce pain to an acceptable level (≤ mild) in a proportion of participants, but the large standard deviations show that the response is variable, and some participants will not achieve good pain relief. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012638-sec-0079"> <h6 class="title">NSAID versus opioid</h6> <p><a href="./references#CD012638-bbs2-0001" title="CarlsonRW , BorrisonRA , SherHB , EisenbergPD , MowryPA , WolinEM . A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy1990;10(3):211‐6. [DOI: 10.1002/j.1875‐9114.1990.tb02577.x] ">Carlson 1990</a> reported that mean daily pain relief was greater for the combination of paracetamol and codeine than ketorolac over seven days, with statistical significance on the second and fourth days of treatment. </p> <p><a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a> reported a physician assessment of therapeutic efficacy of very good occurred in 1/33 participants with diclofenac, 3/33 with nefopam, and 1/33 with codeine plus aspirin. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> </section> <section id="CD012638-sec-0080"> <h5 class="title">Secondary outcomes</h5> <p>None of the studies reported on quality of life or participant satisfaction or preference in cross‐over studies. </p> <section id="CD012638-sec-0081"> <h6 class="title">Use of rescue medication</h6> <p>Two studies reported on the number of participants who used rescue medication during treatment periods. </p> <p>In <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>, 40/57 participants taking dexketoprofen trometamol 100 mg daily and 42/58 taking ketorolac 40 mg daily used rescue medication; the median number of tablets (paracetamol + codeine 500 mg/30 mg) taken over the whole study period was three with dexketoprofen and six with ketorolac. </p> <p>In <a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a>, 17/41 participants taking dipyrone 3000 mg daily, 11/38 taking dipyrone 6000 mg daily, and 12/42 taking morphine 60 mg daily used rescue medication. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> </section> </section> <section id="CD012638-sec-0082"> <h4 class="title">Harm</h4> <section id="CD012638-sec-0083"> <h5 class="title">Serious adverse events and deaths</h5> <p>Nine studies did not report specifically on serious adverse events.</p> <p><a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a> reported two serious adverse events, each with dexketoprofen trometamol 100 mg daily and ketorolac 40 mg daily. One event, gastrointestinal haemorrhage with ketorolac was considered treatment‐related. </p> <p><a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a> reported that there were no adverse events during the study. </p> <p>Deaths were reported separately from adverse events in these studies, probably because most were due to progression of the cancer and not considered relevant to the study drugs. </p> <p>Twenty‐two deaths were reported in the 11 studies. <a href="./references#CD012638-bbs2-0002" title="CantarelliA , GiannunzioD , LigorioL , MapelliA , VecaG , GallucciM , et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica1991;57(10):1103‐4. [PUBMED: 1961495] GallucciM , ToscaniF , MapelliA , CantarelliA , VecaG , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung1992;42(8):1028‐30. [PUBMED: 1418076] ToscaniF , GallucciM , ScaricabarozziI . Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] ">Gallucci 1992</a> reported 5/34 deaths with nimesulide and 9/58 with naproxen, <a href="./references#CD012638-bbs2-0010" title="VentafriddaV , ToscaniF , TamburiniM , CorliO , GallucciM , GottliebA , et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung1990;40(10):1132‐4. [PUBMED: 2291751] ">Ventafrida 1990a</a> reported 2/50 deaths with naproxen and 2/50 with diclofenac, and <a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a> reported two deaths, judged unrelated to treatment (group not given). These studies enrolled participants with advanced cancers. <a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a> reported one death with dexketoprofen, and <a href="./references#CD012638-bbs2-0011" title="YalçinS , GüllüIH , TekuzmanG , SavaşC , FiratD . A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology1998;21(2):185‐8. [PUBMED: 9537209] ">Yalçin 1998</a> reported one death (group not given) due to progression of the disease. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012638-sec-0084"> <h5 class="title">Specific adverse events</h5> <p>For cancer patients we were particularly interested in somnolence, loss of appetite (or anorexia), and thirst (or dry mouth), which have been highlighted as of concern (<a href="./references#CD012638-bbs2-0126" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>). Where results were reported at one week and two weeks, we have used the one week data for consistency with other studies. </p> <p><a href="./references#CD012638-bbs2-0009" title="TurnbullR , HillsLJ . Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care1986;1(2):25‐8. [PUBMED: 3450812] ">Turnbull 1986</a> reported that there were no adverse events with either treatment in 28 participants. While all the remaining studies reported some information on specific adverse events, the categories that were reported (e.g. the most common, those that were of "high intensity") differed, as did the descriptions of the events. It was often difficult to determine which events could be counted together (e.g. somnolence, tiredness, sleepiness, fatigue; or dyspepsia, stomach pain, gastralgia). There were no obvious differences between treatment groups within a study. </p> <p>There were 47 somnolence events reported in 543 participants (9%) in seven comparisons of NSAID versus NSAID, and 22 amongst 115 participants (19%) taking an opioid (or opioid combination) in three comparisons with NSAIDs. </p> <p>There were 11 anorexia events reported in 313 participants (4%) in four comparisons of NSAID versus NSAID, and two amongst 82 participants (2%) taking an opioid (or opioid combination) in two comparisons with NSAIDs. </p> <p>There were 23 dry mouth events reported in 234 participants (10%) in three comparisons of NSAID versus NSAID, and two amongst 40 participants (5%) taking an opioid (or opioid combination) in one comparison with an NSAID. </p> <p>Since gastrointestinal events are of concern with NSAIDs, we looked for evidence of a difference in frequency between NSAIDs and between NSAIDs and opioids (or opioid combinations). There were no obvious differences between treatment groups within a study. </p> <p>Dyspepsia or epigastric pain was one of the more common specific gastrointestinal events reported. There were 83 events in 971 participants (9%) in 10 comparisons of NSAID versus NSAID, and nine amongst 115 participants (8%) taking an opioid (or opioid combination) in three comparisons with NSAIDs. </p> <p>We assessed all evidence on specific adverse events as very low quality because of high risk of bias and small size. </p> </section> <section id="CD012638-sec-0085"> <h5 class="title">Withdrawals</h5> <section id="CD012638-sec-0086"> <h6 class="title">All‐cause</h6> <p>There were 204 withdrawals for any reason reported amongst 874 participants (23%) in 10 comparisons of NSAID versus NSAID, and 48 amongst 73 participants (66%) taking an opioid (or opioid combination) in two comparisons with NSAIDs. It was not always clear whether reported withdrawals included participants who progressed to step II analgesics. There were no obvious differences between treatment groups. </p> </section> <section id="CD012638-sec-0087"> <h6 class="title">Lack of efficacy</h6> <p>There were 136 withdrawals due to lack of efficacy reported amongst 567 participants (24%) in 14 comparisons of NSAID versus NSAID, and 17 amongst 73 participants (23%) taking an opioid (or opioid combination) in two comparisons with NSAIDs. There were no obvious differences between treatment groups. Some studies reported lack of efficacy withdrawals, some reported participants progressing to step II (we judged probably due to lack of efficacy), some reported neither, and others reported both. It is difficult to interpret these numbers in a situation where the natural course of the disease is likely to require progression to step II. </p> </section> <section id="CD012638-sec-0088"> <h6 class="title">Adverse events</h6> <p>Withdrawals due to adverse events were not common; 39 events were reported for 718 participants (5%) in 17 comparisons of NSAID versus NSAID, and 10 events reported for 115 participants taking an opioid (9%) or opioid combination) in three comparisons with NSAIDs. There were no obvious differences between treatment groups, and too few events for analysis. </p> <p>We assessed all evidence on withdrawals as very low quality because of high risk of bias and small size.. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012638-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012638-sec-0089"></div> <section id="CD012638-sec-0090"> <h3 class="title" id="CD012638-sec-0090">Summary of main results</h3> <p>Few studies met the criteria for inclusion, and together with the nature of the efficacy results presented, the results of the available studies for NSAIDs for cancer pain are insufficient to allow any conclusions to be drawn about efficacy or harm. The evidence is insufficient to support or refute their use. </p> <p>No studies were found for the use of NSAIDs alone in mild or moderate cancer pain, as suggested for the first step of the WHO analgesic ladder (<a href="./references#CD012638-bbs2-0125" title="Anonymous . WHO analgesic ladder. who.int/cancer/palliative/painladder/en/ (accessed 7 February 2017). ">WHO 2017</a>). Included studies typically had initial pain that was moderate or severe in intensity. No studies were found examining the additional analgesic efficacy of NSAIDs combined with strong opioids. </p> <p>The 11 included studies randomised 949 participants with cancer pain, predominantly of moderate or severe intensity. Studies typically compared one NSAID with another, though a few compared an NSAID with an opioid or opioid combination. In this circumstance no comparative analyses were possible. What was possible was an assessment of the proportion of participants who had a pain score of no or mild pain (or some equivalent measure) around one or two weeks following the start of NSAID treatment. This was highly variable, with assessments of 3% for a physician assessment of very good efficacy (<a href="./references#CD012638-bbs2-0003" title="MinottiV , PatoiaL , RoilaF , BasurtoC , TonatoM , PasqualucciV , et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain1989;36(2):177‐83. [DOI: 10.1016/0304‐3959(89)90021‐3] ">Minotti 1989</a>) or 7% for participant evaluation of complete relief (<a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a>), to 26% for complete or good relief (<a href="./references#CD012638-bbs2-0005" title="PannutiF , Robustelli della CunaG , VentaffridaV , StrocchiE , CamaggiCM . A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori1999;85(2):96‐100. [PUBMED: 10363074] ">Pannuti 1999</a>), 52% for overall analgesic efficacy good or excellent (<a href="./references#CD012638-bbs2-0006" title="RodríguezM , BarutellC , RullM , GálvezR , PallarésJ , VidalF , et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer1994;30A(5):584‐7. [PUBMED: 8080670] ">Rodriguez 1994</a>), and 51% for pain intensity of below 30/100 mm on the final day of treatment (<a href="./references#CD012638-bbs2-0007" title="RodríguezMJ , ContrerasD , GálvezR , CastroA , CambaMA , BusquetsC , et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain2003;104(1‐2):103‐10. [DOI: 10.1016/S0304‐3959(02)00470‐0] ">Rodriguez 2003</a>). One other study, while providing no comparable results, also reported a mean integrated pain score equivalent to all‐day slight pain or below at one and two weeks (<a href="./references#CD012638-bbs2-0010" title="VentafriddaV , ToscaniF , TamburiniM , CorliO , GallucciM , GottliebA , et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung1990;40(10):1132‐4. [PUBMED: 2291751] ">Ventafrida 1990a</a>). This impression of efficacy was also seen in a study excluded for its small size for individual NSAIDs, but which was essentially a randomised cohort study of NSAIDs given to 65 participants with moderate or severe cancer pain (<a href="./references#CD012638-bbs2-0043" title="VentafriddaV , DeConnoF , PaneraiAE , MarescaV , MonzaGC , RipamontiC . Non‐steroidal anti‐inflammatory drugs as the first step in cancer pain therapy: double‐blind, within‐patient study comparing nine drugs. Journal of International Medical Research1990;18(1):21‐9. [PUBMED: 2185963] ">Ventafridda 1990b</a>); pain scores were below 30/100 at one and two weeks for seven of eight NSAIDs tested. </p> <p>Reporting of harms provided no useful information, and could not be expected to do so given the small size of the studies, individually and together. There are limits on how comparable adverse event information can be, but for particular adverse events, such as somnolence (11%), loss of appetite (14%), or thirst or dry mouth (15%), rates with NSAIDs were similar to those found with opioids (somnolence 23%, anorexia 17%, dry mouth 17%) (<a href="./references#CD012638-bbs2-0126" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>). </p> <p>A large number of studies were excluded, mainly because of short treatment duration or their very small size limiting applicability. </p> <p>Where there are small numbers of small studies, there is a situation where a positive bias in favour of a therapy might be found (<a href="./references#CD012638-bbs2-0062" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartes 2013</a>; <a href="./references#CD012638-bbs2-0063" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012638-bbs2-0074" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the United States of America2017;114(14):3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD012638-bbs2-0106" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology2017;84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>; <a href="./references#CD012638-bbs2-0108" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>) even by the random play of chance (<a href="./references#CD012638-bbs2-0052" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD012638-bbs2-0095" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012638-bbs2-0119" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>), and overemphasising results of underpowered studies or analyses has been criticised (<a href="./references#CD012638-bbs2-0047" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012638-bbs2-0114" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD012638-bbs2-0120" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). Because of the small number of studies and participants in this review, any reported positive effect of NSAIDs in cancer pain should be treated with caution. </p> <p>NSAIDs are known to have good efficacy in acute postoperative pain (<a href="./references#CD012638-bbs2-0103" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Single dose oral analgesics for acute postoperative pain in adults ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD008659.pub3] ">Moore 2015a</a>), migraine (<a href="./references#CD012638-bbs2-0112" title="RabbieR , DerryS , MooreRA . Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008039.pub3] ">Rabbie 2013</a>), and dysmenorrhoea (<a href="./references#CD012638-bbs2-0070" title="EdwardsJE , MooreRA , McQuayHJ . Rofecoxib for dysmenorrhoea: meta‐analysis using individual patient data. BMC Womens Health2004;4(1):3. [DOI: 10.1186/1471‐2253‐4‐3] ">Edwards 2004</a>). In chronic pain, they have efficacy in musculoskeletal conditions like arthritis (<a href="./references#CD012638-bbs2-0123" title="vanWalsemA , PandhiS , NixonRM , GuyotP , KarabisA , MooreRA . Relative benefit‐risk comparing diclofenac to other traditional non‐steroidal anti‐inflammatory drugs and cyclooxygenase‐2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta‐analysis. Arthritis Research and Therapy2015;17:66. [DOI: 10.1186/s13075‐015‐0554‐0] ">van Walsem 2015</a>), but not in neuropathic pain (<a href="./references#CD012638-bbs2-0104" title="MooreRA , ChiCC , WiffenPJ , DerryS , RiceASC . Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD010902.pub2] ">Moore 2015b</a>) or fibromyalgia (<a href="./references#CD012638-bbs2-0066" title="DerryS , WiffenPJ , HäuserW , MückeM , TölleTR , BellRF , et al. Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD012332.pub2] ">Derry 2017</a>). </p> </section> <section id="CD012638-sec-0091"> <h3 class="title" id="CD012638-sec-0091">Overall completeness and applicability of evidence</h3> <p>This review highlights our lack of knowledge about the effectiveness of NSAIDs for cancer pain. The WHO ladder recommends non‐opioid analgesics for all three steps of the WHO ladder (<a href="./references#CD012638-bbs2-0125" title="Anonymous . WHO analgesic ladder. who.int/cancer/palliative/painladder/en/ (accessed 7 February 2017). ">WHO 2017</a>), and NSAIDs in many countries are the mainstay of the first two steps. </p> <p>Not all of the studies reported on primary outcomes of efficacy known to be important to people with pain (<a href="./references#CD012638-bbs2-0099" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> </section> <section id="CD012638-sec-0092"> <h3 class="title" id="CD012638-sec-0092">Quality of the evidence</h3> <p>Our GRADE judgement was very low quality for all outcomes. Very low quality means that this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different is very high. </p> <p>A number of individual studies had high risk of bias for issues such as incomplete outcome data and small size, and none of the trials was unequivocally at low risk of bias for all criteria. </p> </section> <section id="CD012638-sec-0093"> <h3 class="title" id="CD012638-sec-0093">Potential biases in the review process</h3> <p>We are unaware of any biases in the review process. A number of the authors prescribe or have prescribed NSAIDs for cancer pain, or have been involved with its use in people with cancer pain. </p> </section> <section id="CD012638-sec-0094"> <h3 class="title" id="CD012638-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are in broad agreement with a previous Cochrane review (<a href="./references#CD012638-bbs2-0133" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>) and other reviews in adults (<a href="./references#CD012638-bbs2-0093" title="MercadanteS , GiarratanoA . The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Mercadante 2013</a>; <a href="./references#CD012638-bbs2-0105" title="NabalM , LibradaS , RedondoMJ , PigniA , BrunelliC , CaraceniA . The role of paracetamol and nonsteroidal anti‐inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliative Medicine2012;26(4):305‐12. [DOI: 10.1177/0269216311428528] ">Nabal 2012</a>). In this review we included only studies with a minimum treatment period of five days, excluding some studies of short duration in these earlier reviews, but allowing any pain‐relieving effects of NSAIDs that might be seen in clinical practice to emerge. We also excluded very small studies. That meant that we excluded some studies in these previous reviews. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012638-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/urn:x-wiley:14651858:media:CD012638:CD012638-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_t/tCD012638-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012638-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_n/nCD012638-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_n/nCD012638-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012638-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/urn:x-wiley:14651858:media:CD012638:CD012638-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_t/tCD012638-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD012638-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_n/nCD012638-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/media/CDSR/CD012638/image_n/nCD012638-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012638-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>NSAID for cancer pain ‐ non‐controlled data</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer pain </p> <p><b>Settings:</b> inpatient or outpatient </p> <p><b>Intervention:</b> any NSAID, and dose </p> <p><b>Comparison:</b> no control ‐ cohort of treated participants </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with NSAID</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants with at least 30% or at least 50% reduction in pain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC much or very much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain no worse than mild at one or two weeks (or equivalent)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Range of estimates from 260 in 1000 to 510 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 studies</p> <p>415 participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 serious adverse events reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 studies</p> <p>949 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Dry mouth 10%</p> <p>Loss of appetite 4%</p> <p>Somnolence 9%</p> <p>Dyspepsia 9%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Variously reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>All cause 23%</p> <p>Lack of efficacy 24%</p> <p>Adverse event 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Variously reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 deaths, not clearly related to treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 studies</p> <p>949 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited data, several risks of bias</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD012638-bbs2-0073" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 7 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> This research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012638.pub2/full#CD012638-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012638.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012638-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012638-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012638-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012638-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012638-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012638-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012638-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012638-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012638\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012638\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012638\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012638\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012638.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012638.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012638.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012638.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012638.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717084218"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012638.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717084222"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012638.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daf4a0921936e',t:'MTc0MDcxNzA4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 